Epidemiology of Gout in French Polynesia

Gout Clinical Trial

— TOPATA  

Official title:

Gout in French Polynesia: Epidemiology and Comorbidities, Genetic Causes and Prevalence of HLA B58:01

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04812886
• Other study ID #: RC-P00104
• Status: Completed
• Phase: N/A
• Start date: April 29, 2021
• Est. completion date: August 16, 2021

Study information

• Verified date: September 2021
• Source: Lille Catholic University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Gout is a chronic disease caused by the deposit of monosodium urate (MSU) crystals in body tissues secondary to hyperuricemia. Patients with gout suffer severe attacks of acute joint pain. As the disease progresses, the joint pain becomes chronic and associated with disabling and deformative manifestations called tophi. Gout is strongly associated with various comorbidities including cardiovascular disease and chronic kidney failure. Gout is a very common disease, affecting 0.9% of the adult population in France and nearly 4% of the North-American population. Data from New Zealand show a particularly high prevalence of gout among Polynesians (minority populations in New Zealand and other islands of the South Pacific) that would be explained by genetic susceptibility and frequently intertwined with metabolic diseases. Recent findings obtained from the Polynesian population in New Caledonia disclose high prevalence figures close to 7%, a level expected to be confirmed by an epidemiology study that will be conducted in parallel with the present study and designed to determine the precise prevalence of gout in French Polynesia and the most frequently associated genetic variants.

Description:

International genomic studies conducted in populations with hyperuricemia and gout have identified a number of associated alleles. The strength of the association between a given allele and gout (or hyperuricemia) provides an indication of the importance of the encoded protein in disease pathogenesis. It was in this way that the development of gout was found to depend on renal urate transporters that were subsequently targeted by new uricosuric therapies. Overall, the search for gout-associated genes has mostly been done in the general European population and revealed a small number of candidate loci. Most of these only contribute a small amount to the heritability for gout susceptibility, suggesting that additional genes and mechanisms of genetic influence are yet to be discovered. A common feature of Genome-Wide Association studies done so far is that usually large sample sizes are required in order to detect differences in allele frequencies and their contribution to different traits between test groups. The Polynesian population of French Polynesia possesses characteristics that make it particularly attractive to carry out population-based genetic research. Historical records indicate that the Polynesians of Tahiti and surrounding islands originate from a small founder population that has undergone a number of bottlenecks, eventually becoming a genetically homogenous population with a fairly high degree of consanguinity. The combination of a historic founder event, continued isolation and recent expansion are all ideal properties for a Genome Wide Association Study, as they ensure that 1) population stratification will be easy to correct when performing association tests and 2) there are likely high-effect variants that were kept at low frequency in mainland Europe due to negative selection but rose to high frequencies in the Polynesians via the increase in genetic drift or selection through adaptation to a specific environment and diet. Therefore, it is plausible that rare variants with large effect on health-related quantitative traits may be more easily detectable in Polynesians, even with much smaller sample sizes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1088
• Est. completion date: August 16, 2021
• Est. primary completion date: August 16, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Living in Tahiti, Moorea, Tahaa-Raiatea, Tikehau, Nuku Hiva, Mangareva, Rurutu
• Agreeing to participate in the study

Exclusion Criteria:

• Homeless
• Living in communities (military camp, hospices, university residence, ...)
• Unable to answer questionnaires
• Under guardianship

Related Conditions & MeSH terms

• Gout

Intervention

Other:
• Epidemiological study
Questionnaires (quality of life, gout, life habit, comorbidities) anthropometrics and health measures DNA analysis RNA analysis Metabolomic analysis

Locations

Country	Name	City	State
French Polynesia	Centre Hospitalier de la Polynésie Française	Pirae

Sponsors (5)

Lead Sponsor	Collaborator
Lille Catholic University	Ministry of Health, French Polynesia, University of Birmingham, University of San Diego, Variant Bio, Inc.

Country where clinical trial is conducted

French Polynesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gout Prevalence	Measure of gout prevalence	6 months
Secondary	Diagnosis of Hyperuricemia	Diagnosed when uricemia is higher than 360 µmol/l	6 months
Secondary	Genome wide analysis for identification of genetic variants linked to gout	Analysis of the genetic determinants of gout and hyperuricemia in French Polynesia via a pan-genomic analysis using complete and then rapid sequencing techniques	6 months
Secondary	HLA B58:01 allele prevalence		6 months
Secondary	Multiple correlation between renal failure, diabetes, gout and cardiovascular comorbidities	The association between cardiovascular comorbidities/renal failure/diabetes and gout will be investigated using a multivariate logistic regression model.	6 months
Secondary	Multiple correlation between renal failure, diabetes, hyperuricemia and cardiovascular comorbidities	The association between cardiovascular comorbidities/renal failure/diabetes and hyperuricemia will be investigated using a multivariate logistic regression model.	6 months